TY - JOUR AU - Leach, D. R. AU - Krummel, M. F. AU - Allison, J. P. PY - 1996 DA - 1996// TI - Enhancement of Antitumor Immunity by CTLA-4 Blockade JO - Science VL - 271 UR - https://doi.org/10.1126/science.271.5256.1734 DO - 10.1126/science.271.5256.1734 ID - Leach1996 ER - TY - JOUR AU - Hodi, F. S. AU - O’Day, S. J. AU - McDermott, D. F. AU - Weber, R. W. AU - Sosman, J. A. AU - Haanen, J. B. PY - 2010 DA - 2010// TI - Improved survival with Ipilimumab in patients with metastatic melanoma JO - N Engl J Med VL - 363 UR - https://doi.org/10.1056/NEJMoa1003466 DO - 10.1056/NEJMoa1003466 ID - Hodi2010 ER - TY - STD TI - Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung Cancer. N Engl J Med. 2016. ID - ref3 ER - TY - STD TI - Overman MJ, Lonardi S, Leone F, Mcdermott RS, Morse MA, Yeung K, et al. Nivolumab in patients with DNA mismatch repair deficient/microsatellite instability high metastatuc colorectal cancer. ASCO. 2017;2017. ID - ref4 ER - TY - STD TI - Motzer RJ, Tannir NM, DF MD, Arén Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018. ID - ref5 ER - TY - STD TI - Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med [Internet]. 2015;372(26):2509–20. ID - ref6 ER - TY - CHAP AU - Callahan, M. a. r. g. a. r. e. t. K. AU - Flaherty, C. a. t. h. e. r. i. n. e. R. AU - Postow, M. i. c. h. a. e. l. A. PY - 2015 DA - 2015// TI - Checkpoint Blockade for the Treatment of Advanced Melanoma BT - Melanoma PB - Springer International Publishing CY - Cham ID - Callahan2015 ER - TY - STD TI - Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non–small-cell lung Cancer. N Engl J Med. 2018. ID - ref8 ER - TY - STD TI - Malhotra J, Jabbour SK, Aisner J. Current state of immunotherapy for non-small cell lung cancer. Transl Lung Cancer Res. 2017. ID - ref9 ER - TY - STD TI - Royal RE, Levy C, Turner K, Mathur A, Hughes M, Kammula US, et al. Phase 2 trial of single agent ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother. 2010. ID - ref10 ER - TY - STD TI - Kunk PR, Bauer TW, Slingluff CL, Rahma OE. From bench to bedside a comprehensive review of pancreatic cancer immunotherapy. J Immunother Cancer [Internet]. 2016;4(1):14. ID - ref11 ER - TY - STD TI - Ventola CL. Cancer immunotherapy, part 3: challenges and future trends. P T. 2017. ID - ref12 ER - TY - STD TI - Alatrash G, Jakher H, Stafford PD, Mittendorf EA. Cancer immunotherapies, their safety and toxicity. Expert Opin Drug Saf. 2013. ID - ref13 ER - TY - STD TI - Zugazagoitia J, Guedes C, Ponce S, Ferrer I, Molina-Pinelo S, Paz-Ares L. Current Challenges in Cancer Treatment. Clinical Therapeutics. 2016. ID - ref14 ER - TY - STD TI - Son B, Lee S, Youn H, Kim E, Kim W, Youn B. The role of tumor microenvironment in therapeutic resistance. Oncotarget [Internet]. 2017;8(3):3933–45. ID - ref15 ER - TY - JOUR AU - Balkwill, F. R. AU - Capasso, M. AU - Hagemann, T. PY - 2012 DA - 2012// TI - The tumor microenvironment at a glance JO - Journal of Cell Science VL - 125 UR - https://doi.org/10.1242/jcs.116392 DO - 10.1242/jcs.116392 ID - Balkwill2012 ER - TY - JOUR AU - Postow, M. i. c. h. a. e. l. A. AU - Chesney, J. a. s. o. n. AU - Pavlick, A. n. n. a. C. AU - Robert, C. a. r. o. l. i. n. e. AU - Grossmann, K. e. n. n. e. t. h. AU - McDermott, D. a. v. i. d. AU - Linette, G. e. r. a. l. d. P. AU - Meyer, N. i. c. o. l. a. s. AU - Giguere, J. e. f. f. r. e. y. K. AU - Agarwala, S. a. n. j. i. v. S. AU - Shaheen, M. o. n. t. a. s. e. r. AU - Ernstoff, M. a. r. c. S. AU - Minor, D. a. v. i. d. AU - Salama, A. p. r. i. l. K. AU - Taylor, M. a. t. t. h. e. w. AU - Ott, P. a. t. r. i. c. k. A. AU - Rollin, L. i. n. d. a. M. AU - Horak, C. h. r. i. s. t. i. n. e. AU - Gagnier, P. a. u. l. AU - Wolchok, J. e. d. d. D. AU - Hodi, F. S. t. e. p. h. e. n. PY - 2015 DA - 2015// TI - Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma JO - New England Journal of Medicine VL - 372 UR - https://doi.org/10.1056/NEJMoa1414428 DO - 10.1056/NEJMoa1414428 ID - Postow2015 ER - TY - JOUR AU - Hodi, F. S. S. AU - Chesney, J. AU - Pavlick, A. C. C. AU - Robert, C. AU - Grossmann, K. F. F. AU - McDermott, D. F. F. PY - 2016 DA - 2016// TI - Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial JO - Lancet Oncol VL - 17 UR - https://doi.org/10.1016/S1470-2045(16)30366-7 DO - 10.1016/S1470-2045(16)30366-7 ID - Hodi2016 ER - TY - JOUR AU - Wang-Gillam, A. n. d. r. e. a. AU - Lockhart, A. C. r. a. i. g. AU - Tan, B. e. n. j. a. m. i. n. R. AU - Suresh, R. a. m. a. AU - Lim, K. i. a. n. -. H. u. a. t. AU - Ratner, L. e. e. AU - Morton, A. s. h. l. e. y. AU - Huffman, J. e. s. s. AU - Marquez, S. a. m. a. n. t. h. a. AU - Boice, N. i. c. o. l. a. s. AU - DeNardo, D. a. v. i. d. G. PY - 2018 DA - 2018// TI - Phase I study of defactinib combined with pembrolizumab and gemcitabine in patients with advanced cancer JO - Journal of Clinical Oncology VL - 36 UR - https://doi.org/10.1200/JCO.2018.36.4_suppl.380 DO - 10.1200/JCO.2018.36.4_suppl.380 ID - Wang-Gillam2018 ER - TY - STD TI - Lavanya V, Adil M, Ahmed N, Rishi AK, Jamal S. Small molecule inhibitors as emerging cancer therapeutics. Integr Cancer Sci Ther Integr Cancer Sci Ther. 2014. ID - ref20 ER - TY - JOUR AU - Tsujikawa, T. AU - Kumar, S. AU - Borkar, R. N. AU - Azimi, V. AU - Thibault, G. AU - Chang, Y. H. PY - 2017 DA - 2017// TI - Quantitative multiplex immunohistochemistry reveals myeloid-inflamed tumor-immune complexity associated with poor prognosis JO - Cell Rep VL - 19 UR - https://doi.org/10.1016/j.celrep.2017.03.037 DO - 10.1016/j.celrep.2017.03.037 ID - Tsujikawa2017 ER - TY - STD TI - Dai XM, Ryan GR, Hapel AJ, Dominguez MG, Russell RG, Kapp S, et al. Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects. Blood. 2002. ID - ref22 ER - TY - JOUR AU - Liu, H. a. o. AU - Zhang, H. e. n. g. AU - Shen, Z. h. e. n. b. i. n. AU - Lin, C. h. a. o. AU - Wang, X. u. e. f. e. i. AU - Qin, J. i. n. g. AU - Qin, X. i. n. y. u. AU - Xu, J. i. e. j. i. e. AU - Sun, Y. i. h. o. n. g. PY - 2016 DA - 2016// TI - Increased Expression of CSF-1 Associates With Poor Prognosis of Patients With Gastric Cancer Undergoing Gastrectomy JO - Medicine VL - 95 UR - https://doi.org/10.1097/MD.0000000000002675 DO - 10.1097/MD.0000000000002675 ID - Liu2016 ER - TY - JOUR AU - Zhu, Y. AU - Knolhoff, B. L. AU - Meyer, M. A. AU - Nywening, T. M. AU - West, B. L. AU - Luo, J. PY - 2014 DA - 2014// TI - CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models JO - Cancer Res VL - 74 UR - https://doi.org/10.1158/0008-5472.CAN-13-3723 DO - 10.1158/0008-5472.CAN-13-3723 ID - Zhu2014 ER - TY - JOUR AU - Saung, M. T. AU - Muth, S. AU - Ding, D. AU - Thomas, D. L. AU - Blair, A. B. AU - Tsujikawa, T. PY - 2018 DA - 2018// TI - Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer JO - J Immunother cancer VL - 6 UR - https://doi.org/10.1186/s40425-018-0435-6 DO - 10.1186/s40425-018-0435-6 ID - Saung2018 ER - TY - STD TI - Golubovskaya V. Targeting FAK in human cancer: from finding to first clinical trials. Front Biosci. 2014. ID - ref26 ER - TY - STD TI - Mahadevan D, Von Hoff DD. Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther. 2007. ID - ref27 ER - TY - STD TI - Vonderheide RH, Lorusso PM, Khalil M, Gartner EM, Khaira D, Soulieres D, et al. Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells. Clin Cancer Res. 2010. ID - ref28 ER - TY - STD TI - Vonderheide RH, Domchek SM, Clark AS. Immunotherapy for breast cancer: what are we missing? Clin Cancer res. 2017. ID - ref29 ER - TY - STD TI - Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008. ID - ref30 ER - TY - JOUR AU - Kiss, M. a. t. e. AU - Van Gassen, S. o. f. i. e. AU - Movahedi, K. i. a. v. a. s. h. AU - Saeys, Y. v. a. n. AU - Laoui, D. a. m. y. a. PY - 2018 DA - 2018// TI - Myeloid cell heterogeneity in cancer: not a single cell alike JO - Cellular Immunology VL - 330 UR - https://doi.org/10.1016/j.cellimm.2018.02.008 DO - 10.1016/j.cellimm.2018.02.008 ID - Kiss2018 ER - TY - JOUR AU - Engblom, C. a. m. i. l. l. a. AU - Pfirschke, C. h. r. i. s. t. i. n. a. AU - Pittet, M. i. k. a. e. l. J. PY - 2016 DA - 2016// TI - The role of myeloid cells in cancer therapies JO - Nature Reviews Cancer VL - 16 UR - https://doi.org/10.1038/nrc.2016.54 DO - 10.1038/nrc.2016.54 ID - Engblom2016 ER - TY - STD TI - Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nature Communications. 2016. ID - ref33 ER - TY - STD TI - Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, et al. Polarization of tumor-associated neutrophil phenotype by TGF-β: “N1” versus “N2” TAN. Cancer Cell. 2009. ID - ref34 ER - TY - STD TI - Ugel S, De Sanctis F, Mandruzzato S, Bronte V. Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages. J Clin Investig. 2015. ID - ref35 ER - TY - STD TI - Whiteside TL. Immune responses to malignancies. J Allergy Clin Immunol. 2010. ID - ref36 ER - TY - JOUR AU - Pedersen, M. B. AU - Danielsen, A. V. AU - Hamilton-Dutoit, S. J. AU - Bendix, K. AU - Nørgaard, P. AU - Møller, M. B. PY - 2014 DA - 2014// TI - High intratumoral macrophage content is an adverse prognostic feature in anaplastic large cell lymphoma JO - Histopathology. VL - 65 UR - https://doi.org/10.1111/his.12407 DO - 10.1111/his.12407 ID - Pedersen2014 ER - TY - JOUR AU - Murray, P. e. t. e. r.  . J. AU - Allen, J. u. d. i. t. h.  . E. AU - Biswas, S. u. b. h. r. a.  . K. AU - Fisher, E. d. w. a. r. d.  . A. AU - Gilroy, D. e. r. e. k.  . W. AU - Goerdt, S. e. r. g. i. j. AU - Gordon, S. i. a. m. o. n. AU - Hamilton, J. o. h. n.  . A. AU - Ivashkiv, L. i. o. n. e. l.  . B. AU - Lawrence, T. o. b. y. AU - Locati, M. a. s. s. i. m. o. AU - Mantovani, A. l. b. e. r. t. o. AU - Martinez, F. e. r. n. a. n. d. o.  . O. AU - Mege, J. e. a. n. -. L. o. u. i. s. AU - Mosser, D. a. v. i. d.  . M. AU - Natoli, G. i. o. a. c. c. h. i. n. o. AU - Saeij, J. e. r. o. e. n.  . P. AU - Schultze, J. o. a. c. h. i. m.  . L. AU - Shirey, K. a. r. i.  . A. n. n. AU - Sica, A. n. t. o. n. i. o. AU - Suttles, J. i. l. l. AU - Udalova, I. r. i. n. a. AU - van Ginderachter, J. o.  . A. AU - Vogel, S. t. e. f. a. n. i. e.  . N. AU - Wynn, T. h. o. m. a. s.  . A. PY - 2014 DA - 2014// TI - Macrophage Activation and Polarization: Nomenclature and Experimental Guidelines JO - Immunity VL - 41 UR - https://doi.org/10.1016/j.immuni.2014.07.009 DO - 10.1016/j.immuni.2014.07.009 ID - Murray2014 ER - TY - STD TI - Wang B, Li Q, Qin L, Zhao S, Wang J, Chen X. Transition of tumor-associated macrophages from MHC class IIhi to MHC class IIlow mediates tumor progression in mice. BMC Immunol. 2011. ID - ref39 ER - TY - STD TI - Prada CE, Jousma E, Rizvi TA, Wu J, Scott Dunn R, Mayes DA, et al. Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition. Acta Neuropathol. 2013. ID - ref40 ER - TY - JOUR AU - Palma, M. AU - Lewis, C. E. PY - 2013 DA - 2013// TI - Macrophage regulation of tumor responses to anticancer therapies JO - Cancer Cell VL - 23 UR - https://doi.org/10.1016/j.ccr.2013.02.013 DO - 10.1016/j.ccr.2013.02.013 ID - Palma2013 ER - TY - JOUR AU - Kurahara, H. i. r. o. s. h. i. AU - Shinchi, H. i. r. o. y. u. k. i. AU - Mataki, Y. u. k. o. AU - Maemura, K. o. u. s. e. i. AU - Noma, H. i. d. e. t. o. s. h. i. AU - Kubo, F. u. m. i. t. a. k. e. AU - Sakoda, M. a. s. a. h. i. k. o. AU - Ueno, S. h. i. n. i. c. h. i. AU - Natsugoe, S. h. o. j. i. AU - Takao, S. o. n. s. h. i. n. PY - 2011 DA - 2011// TI - Significance of M2-Polarized Tumor-Associated Macrophage in Pancreatic Cancer JO - Journal of Surgical Research VL - 167 UR - https://doi.org/10.1016/j.jss.2009.05.026 DO - 10.1016/j.jss.2009.05.026 ID - Kurahara2011 ER - TY - STD TI - Allegrezza MJ, Conejo-Garcia JR. Targeted therapy and immunosuppression in the tumor microenvironment. Trends in Cancer. 2017. ID - ref43 ER - TY - STD TI - Landskron G, De La Fuente M, Thuwajit P, Thuwajit C, Hermoso MA. Chronic inflammation and cytokines in the tumor microenvironment. Journal of Immunology Research. 2014. ID - ref44 ER - TY - JOUR AU - Pollard, J. W. PY - 2009 DA - 2009// TI - Trophic macrophages in development and disease JO - Nat Rev Immunol VL - 9 UR - https://doi.org/10.1038/nri2528 DO - 10.1038/nri2528 ID - Pollard2009 ER - TY - JOUR AU - Coussens, L. M. AU - Pollard, J. W. PY - 2011 DA - 2011// TI - Leukocytes in mammary development and cancer JO - Cold Spring Harb Perspect Biol VL - 3 UR - https://doi.org/10.1101/cshperspect.a003285 DO - 10.1101/cshperspect.a003285 ID - Coussens2011 ER - TY - STD TI - Fujimura T, Kambayashi Y, Aiba S. Crosstalk between regulatory T cells (Tregs) and myeloid derived suppressor cells (MDSCs) during melanoma growth. OncoImmunology. 2012. ID - ref47 ER - TY - STD TI - Roca H, Varcos ZS, Sud S, Craig MJ, Pienta KJ. CCL2 and interleukin-6 promote survival of human CD11b+ peripheral blood mononuclear cells and induce M2-type macrophage polarization. J Biol Chem. 2009. ID - ref48 ER - TY - STD TI - Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nature Reviews Cancer. 2008. ID - ref49 ER - TY - STD TI - Mantovani A, Allavena P, Sica A. Tumour-associated macrophages as a prototypic type II polarised phagocyte population: role in tumour progression. Eur J Cancer. 2004. ID - ref50 ER - TY - JOUR AU - Mantovani, A. PY - 2008 DA - 2008// TI - Inflaming metastasis JO - Nature VL - 457 UR - https://doi.org/10.1038/457036b DO - 10.1038/457036b ID - Mantovani2008 ER - TY - JOUR AU - Kim, S. AU - Takahashi, H. AU - Lin, W. W. AU - Descargues, P. AU - Grivennikov, S. AU - Kim, Y. PY - 2009 DA - 2009// TI - Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis JO - Nature. VL - 457 UR - https://doi.org/10.1038/nature07623 DO - 10.1038/nature07623 ID - Kim2009 ER - TY - STD TI - Rovida Elisabetta, Lugli Benedetta, Barbetti Valentina, Giuntoli Serena, Olivotto Massimo, Dello Sbarba Persio. Focal adhesion kinase is redistributed to focal complexes and mediates cell spreading in macrophages in response to M-CSF [Internet]. Biological Chemistry. 2005;386:919. ID - ref53 ER - TY - JOUR AU - Owen, K. A. AU - Pixley, F. J. AU - Thomas, K. S. AU - Vicente-Manzanares, M. AU - Ray, B. J. AU - Horwitz, A. F. PY - 2007 DA - 2007// TI - Regulation of lamellipodial persistence, adhesion turnover, and motility in macrophages by focal adhesion kinase JO - J Cell Biol VL - 179 UR - https://doi.org/10.1083/jcb.200708093 DO - 10.1083/jcb.200708093 ID - Owen2007 ER - TY - JOUR AU - Digiacomo, G. AU - Tusa, I. AU - Bacci, M. AU - Cipolleschi, M. G. AU - Sbarba, P. AU - Rovida, E. PY - 2017 DA - 2017// TI - Fibronectin induces macrophage migration through a SFK-FAK/CSF-1R pathway JO - Cell Adhes Migr VL - 11 UR - https://doi.org/10.1080/19336918.2016.1221566 DO - 10.1080/19336918.2016.1221566 ID - Digiacomo2017 ER - TY - STD TI - Zhou S, Khanal S, Zhang H. Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients. Ther Clin Risk Manag [Internet]. 2019;15:211–21. ID - ref56 ER - TY - STD TI - Shoushtari AN, Friedman CF, Navid-Azarbaijani P, Postow MA, Callahan MK, Momtaz P, et al. Measuring toxic effects and time to treatment failure for nivolumab plus ipilimumab in melanoma. JAMA Oncology. 2018. ID - ref57 ER - TY - STD TI - Cheng B, Yuan WE, Su J, Liu Y, Chen J. Recent advances in small molecule based cancer immunotherapy. European Journal of Medicinal Chemistry. 2018. ID - ref58 ER - TY - STD TI - Schwab M, editor. Small Molecule BT - Encyclopedia of Cancer. In Berlin, Heidelberg: Springer Berlin Heidelberg; 2011. p. 3448. Available from: https://doi.org/10.1007/978-3-642-16483-5_5373. ID - ref59 ER - TY - CHAP AU - Yip, K. e. n. n. e. t. h. W. AU - Liu, F. e. i. -. F. e. i. PY - 2011 DA - 2011// TI - Small Molecule Screens BT - Encyclopedia of Cancer PB - Springer Berlin Heidelberg CY - Berlin, Heidelberg UR - https://doi.org/10.1007/978-3-642-16483-5_5376 DO - 10.1007/978-3-642-16483-5_5376 ID - Yip2011 ER - TY - STD TI - Hoelder S, Clarke PA, Workman P. Discovery of small molecule cancer drugs: successes, challenges and opportunities. Mol Oncol. 2012. ID - ref61 ER - TY - STD TI - Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nature Reviews Cancer. 2006. ID - ref62 ER - TY - STD TI - Dancey J, Sausville EA. Issues and progress with protein kinase inhibitors for cancer treatment. Nature Reviews Drug Discovery. 2003. ID - ref63 ER - TY - STD TI - Lim STS. Nuclear FAK. A new mode of gene regulation from cellular adhesions. Molecules and Cells. 2013. ID - ref64 ER - TY - STD TI - Baker M. Upping the ante on antibodies. Nat Biotechnol. 2005. ID - ref65 ER - TY - JOUR AU - Serrels, A. AU - Lund, T. AU - Serrels, B. AU - Byron, A. AU - McPherson, R. C. AU - Kriegsheim, A. PY - 2015 DA - 2015// TI - Nuclear FAK controls chemokine transcription, Tregs, and evasion of anti-tumor immunity JO - Cell. VL - 163 UR - https://doi.org/10.1016/j.cell.2015.09.001 DO - 10.1016/j.cell.2015.09.001 ID - Serrels2015 ER - TY - JOUR AU - Jiang, H. o. n. g. AU - Hegde, S. a. m. a. r. t. h. AU - Knolhoff, B. r. e. t. t. L. AU - Zhu, Y. u. AU - Herndon, J. o. h. n. M. AU - Meyer, M. e. l. i. s. s. a. A. AU - Nywening, T. i. m. o. t. h. y. M. AU - Hawkins, W. i. l. l. i. a. m. G. AU - Shapiro, I. r. i. n. a. M. AU - Weaver, D. a. v. i. d. T. AU - Pachter, J. o. n. a. t. h. a. n. A. AU - Wang-Gillam, A. n. d. r. e. a. AU - DeNardo, D. a. v. i. d. G. PY - 2016 DA - 2016// TI - Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy JO - Nature Medicine VL - 22 UR - https://doi.org/10.1038/nm.4123 DO - 10.1038/nm.4123 ID - Jiang2016 ER - TY - JOUR AU - Poon, E. AU - Mullins, S. AU - Watkins, A. AU - Williams, G. S. AU - Koopmann, J. O. AU - Genova, G. PY - 2017 DA - 2017// TI - The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment JO - J Immunother Cancer VL - 5 UR - https://doi.org/10.1186/s40425-017-0268-8 DO - 10.1186/s40425-017-0268-8 ID - Poon2017 ER - TY - JOUR AU - Murphy, A. d. r. i. a. n. G. AU - Zheng, L. e. i. PY - 2015 DA - 2015// TI - Small molecule drugs with immunomodulatory effects in cancer JO - Human Vaccines & Immunotherapeutics VL - 11 UR - https://doi.org/10.1080/21645515.2015.1057363 DO - 10.1080/21645515.2015.1057363 ID - Murphy2015 ER - TY - JOUR AU - Fallarino, F. AU - Grohmann, U. AU - Vacca, C. AU - Bianchi, R. AU - Orabona, C. AU - Spreca, A. PY - 2002 DA - 2002// TI - T cell apoptosis by tryptophan catabolism JO - Cell Death Differ VL - 9 UR - https://doi.org/10.1038/sj.cdd.4401073 DO - 10.1038/sj.cdd.4401073 ID - Fallarino2002 ER - TY - STD TI - Stanley ER, Chitu V. CSF-1 receptor signaling in myeloid cells. Vol. 6, Cold Spring Harbor Perspectives in Biology. 2014. ID - ref71 ER - TY - JOUR AU - Lin, H. AU - Lee, E. AU - Hestir, K. AU - Leo, C. AU - Huang, M. AU - Bosch, E. AU - Halenbeck, R. AU - Wu, G. AU - Zhou, A. AU - Behrens, D. AU - Hollenbaugh, D. AU - Linnemann, T. AU - Qin, M. AU - Wong, J. AU - Chu, K. AU - Doberstein, S. K. AU - Williams, L. T. PY - 2008 DA - 2008// TI - Discovery of a Cytokine and Its Receptor by Functional Screening of the Extracellular Proteome JO - Science VL - 320 UR - https://doi.org/10.1126/science.1154370 DO - 10.1126/science.1154370 ID - Lin2008 ER - TY - STD TI - Li W, Stanley ER. Role of dimerization and modification of the CSF-1 receptor in its activation and internalization during the CSF-1 response. EMBO J. 1991. ID - ref73 ER - TY - JOUR AU - Baccarini, M. AU - Li, W. AU - Sbarba, P. AU - Stanley, E. R. PY - 1991 DA - 1991// TI - Increased phosphorylation of the colony stimulating factor-1 receptor following transmembrane signaling JO - Receptor. VL - 1 ID - Baccarini1991 ER - TY - JOUR AU - Lee, A. W. -. M. AU - States, D. J. PY - 2000 DA - 2000// TI - Both Src-Dependent and -Independent Mechanisms Mediate Phosphatidylinositol 3-Kinase Regulation of Colony-Stimulating Factor 1-Activated Mitogen-Activated Protein Kinases in Myeloid Progenitors JO - Molecular and Cellular Biology VL - 20 UR - https://doi.org/10.1128/MCB.20.18.6779-6798.2000 DO - 10.1128/MCB.20.18.6779-6798.2000 ID - Lee2000 ER - TY - JOUR AU - Huang, N. AU - Zhu, J. L. AU - Deng, X. M. AU - Li, J. B. AU - Lou, J. S. AU - Bo, L. L. PY - 2011 DA - 2011// TI - Impact of ulinastatin on survival and lymphocyte apoptosis in septic mice JO - Acad J Second Mil Med Univ VL - 32 UR - https://doi.org/10.3724/SP.J.1008.2011.00869 DO - 10.3724/SP.J.1008.2011.00869 ID - Huang2011 ER - TY - JOUR AU - Yu, W. AU - Chen, J. AU - Xiong, Y. AU - Pixley, F. J. AU - Yeung, Y. G. AU - Stanley, E. R. PY - 2012 DA - 2012// TI - Macrophage proliferation is regulated through CSF-1 receptor tyrosines 544, 559, and 807 JO - J Biol Chem VL - 287 UR - https://doi.org/10.1074/jbc.M112.355610 DO - 10.1074/jbc.M112.355610 ID - Yu2012 ER - TY - JOUR AU - Sampaio, N. G. AU - Yu, W. AU - Cox, D. AU - Wyckoff, J. AU - Condeelis, J. AU - Stanley, E. R. AU - Pixley, F. J. PY - 2011 DA - 2011// TI - Phosphorylation of CSF-1R Y721 mediates its association with PI3K to regulate macrophage motility and enhancement of tumor cell invasion JO - Journal of Cell Science VL - 124 UR - https://doi.org/10.1242/jcs.075309 DO - 10.1242/jcs.075309 ID - Sampaio2011 ER - TY - STD TI - Cuccarese MF, Dubach JM, Pfirschke C, Engblom C, Garris C, Miller MA, et al. Heterogeneity of macrophage infiltration and therapeutic response in lung carcinoma revealed by 3D organ imaging. Nat Commun. 2017. ID - ref79 ER - TY - STD TI - Mok S, Koya RC, Tsui C, Xu J, Robert L, Wu L, et al. Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy. Cancer Res. 2014. ID - ref80 ER - TY - STD TI - Ngiow SF, Meeth KM, Stannard K, Barkauskas DS, Bollag G, Bosenberg M, et al. Co-inhibition of colony stimulating factor-1 receptor and BRAF oncogene in mouse models of BRAFV600Emelanoma. Oncoimmunology. 2016. ID - ref81 ER - TY - STD TI - Pyonteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L, Quail DF, et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med. 2013. ID - ref82 ER - TY - STD TI - Edwards DK, Sweeney DT, Ho H, Eide CA, Rofelty A, Agarwal A, et al. Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples. Oncotarget [Internet]. 2018;9(37):24576–89. ID - ref83 ER - TY - JOUR AU - DeNardo, D. G. AU - Brennan, D. J. AU - Rexhepaj, E. AU - Ruffell, B. AU - Shiao, S. L. AU - Madden, S. F. PY - 2011 DA - 2011// TI - Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy JO - Cancer Discov VL - 1 UR - https://doi.org/10.1158/2159-8274.CD-10-0028 DO - 10.1158/2159-8274.CD-10-0028 ID - DeNardo2011 ER - TY - STD TI - Pass HI, Lavilla C, Canino C, Goparaju C, Preiss J, Noreen S, et al. Inhibition of the colony-stimulating-factor-1 receptor affects the resistance of lung cancer cells to cisplatin. Oncotarget [Internet]. 2016;7(35):56408–21. ID - ref85 ER - TY - JOUR AU - Butowski, N. AU - Colman, H. AU - Groot, J. F. AU - Omuro, A. M. AU - Nayak, L. AU - Wen, P. Y. PY - 2016 DA - 2016// TI - Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an ivy Foundation early phase clinical trials consortium phase II study JO - Neuro-Oncology VL - 18 UR - https://doi.org/10.1093/neuonc/nov245 DO - 10.1093/neuonc/nov245 ID - Butowski2016 ER - TY - JOUR AU - Anthony, S. P. AU - Puzanov, I. AU - Lin, P. S. AU - Nolop, K. B. AU - West, B. AU - Von Hoff, D. D. PY - 2011 DA - 2011// TI - Pharmacodynamic activity demonstrated in phase I for PLX3397, a selective inhibitor of FMS and Kit JO - Journal of Clinical Oncology VL - 29 UR - https://doi.org/10.1200/jco.2011.29.15_suppl.3093 DO - 10.1200/jco.2011.29.15_suppl.3093 ID - Anthony2011 ER - TY - JOUR AU - Tap, W. i. l. l. i. a. m. D. AU - Gelderblom, H. a. n. s. AU - Stacchiotti, S. i. l. v. i. a. AU - Palmerini, E. m. a. n. u. e. l. a. AU - Ferrari, S. t. e. f. a. n. o. AU - Desai, J. a. y. e. s. h. AU - Bauer, S. e. b. a. s. t. i. a. n. AU - Blay, J. e. a. n. -. Y. v. e. s. AU - Alcindor, T. h. i. e. r. r. y. AU - Ganjoo, K. r. i. s. t. e. n. N. AU - Martin Broto, J. a. v. i. e. r. AU - Ryan, C. h. r. i. s. t. o. p. h. e. r. W. AU - Shuster, D. a. l. e. E. d. w. a. r. d. AU - Zhang, L. i. n. g. AU - Wang, Q. i. a. n. g. AU - Hsu, H. e. n. r. y. AU - Lin, P. a. u. l. S. AU - Tong, S. a. n. d. r. a. AU - Wagner, A. n. d. r. e. w. J. PY - 2018 DA - 2018// TI - Final results of ENLIVEN: A global, double-blind, randomized, placebo-controlled, phase 3 study of pexidartinib in advanced tenosynovial giant cell tumor (TGCT) JO - Journal of Clinical Oncology VL - 36 UR - https://doi.org/10.1200/JCO.2018.36.15_suppl.11502 DO - 10.1200/JCO.2018.36.15_suppl.11502 ID - Tap2018 ER - TY - JOUR AU - West, R. B. AU - Rubin, B. P. AU - Miller, M. A. AU - Subramanian, S. AU - Kaygusuz, G. AU - Montgomery, K. AU - Zhu, S. AU - Marinelli, R. J. AU - De Luca, A. AU - Downs-Kelly, E. AU - Goldblum, J. R. AU - Corless, C. L. AU - Brown, P. O. AU - Gilks, C. B. AU - Nielsen, T. O. AU - Huntsman, D. AU - van de Rijn, M. PY - 2006 DA - 2006// TI - A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells JO - Proceedings of the National Academy of Sciences VL - 103 UR - https://doi.org/10.1073/pnas.0507321103 DO - 10.1073/pnas.0507321103 ID - West2006 ER - TY - STD TI - Wainberg Z, Piha-Paul S, Luke J, Kim E, Thompson J, Pfanzelter N, et al. 32nd Annual Meeting and Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2017): Part One. J Immunother Cancer [Internet]. 2017;5(S2):86. ID - ref90 ER - TY - STD TI - Rugo H, Lopez-Hernandez J, Gomez-Villanueva A, Gupta N, Qian J, Qin Q, et al. ABT-869 in Combination with Paclitaxel (P) as First-Line Treatment in Patients (Pts) with Advanced Breast Cancer. Cancer Res [Internet]. 2009;69(24 Supplement):5076 LP – 5075076. ID - ref91 ER - TY - JOUR AU - McLean, G. o. r. d. o. n. W. AU - Carragher, N. e. i. l. O. AU - Avizienyte, E. g. l. e. AU - Evans, J. e. f. f. AU - Brunton, V. a. l. e. r. i. e. G. AU - Frame, M. a. r. g. a. r. e. t. C. PY - 2005 DA - 2005// TI - The role of focal-adhesion kinase in cancer — a new therapeutic opportunity JO - Nature Reviews Cancer VL - 5 UR - https://doi.org/10.1038/nrc1647 DO - 10.1038/nrc1647 ID - McLean2005 ER - TY - STD TI - Luo M, Guan J-L. Focal adhesion kinase: a prominent determinant in breast cancer initiation, progression and metastasis. Cancer Lett. 2010. ID - ref93 ER - TY - STD TI - Zhao J, Guan JL. Signal transduction by focal adhesion kinase in cancer. Cancer Metastasis Rev. 2009. ID - ref94 ER - TY - JOUR AU - Sulzmaier, F. J. AU - Jean, C. AU - Schlaepfer, D. D. PY - 2014 DA - 2014// TI - FAK in cancer: Mechanistic findings and clinical applications JO - Nature Reviews Cancer VL - 14 UR - https://doi.org/10.1038/nrc3792 DO - 10.1038/nrc3792 ID - Sulzmaier2014 ER - TY - JOUR AU - Stokes, J. B. AU - Adair, S. J. AU - Slack-Davis, J. K. AU - Walters, D. M. AU - Tilghman, R. W. AU - Hershey, E. D. AU - Lowrey, B. AU - Thomas, K. S. AU - Bouton, A. H. AU - Hwang, R. F. AU - Stelow, E. B. AU - Parsons, J. T. AU - Bauer, T. W. PY - 2011 DA - 2011// TI - Inhibition of Focal Adhesion Kinase by PF-562,271 Inhibits the Growth and Metastasis of Pancreatic Cancer Concomitant with Altering the Tumor Microenvironment JO - Molecular Cancer Therapeutics VL - 10 UR - https://doi.org/10.1158/1535-7163.MCT-11-0261 DO - 10.1158/1535-7163.MCT-11-0261 ID - Stokes2011 ER - TY - JOUR AU - Shiga, K. AU - Hara, M. AU - Nagasaki, T. AU - Sato, T. AU - Takahashi, H. AU - Takeyama, H. PY - 2015 DA - 2015// TI - Cancer-associated fibroblasts: Their characteristics and their roles in tumor growth JO - Cancers VL - 7 UR - https://doi.org/10.3390/cancers7040902 DO - 10.3390/cancers7040902 ID - Shiga2015 ER - TY - JOUR AU - Mahadevan, D. AU - Von Hoff, D. D. PY - 2007 DA - 2007// TI - Tumor-stroma interactions in pancreatic ductal adenocarcinoma JO - Molecular Cancer Therapeutics VL - 6 UR - https://doi.org/10.1158/1535-7163.MCT-06-0686 DO - 10.1158/1535-7163.MCT-06-0686 ID - Mahadevan2007 ER - TY - STD TI - Lakins MA, Ghorani E, Munir H, Martins CP, Shields JD. Cancer-associated fibroblasts induce antigen-specific deletion of CD8+T Cells to protect tumour cells. Nat Commun. 2018;9(1). ID - ref99 ER - TY - JOUR AU - Özdemir, B. C. AU - Pentcheva-Hoang, T. AU - Carstens, J. L. AU - Zheng, X. AU - Wu, C. C. AU - Simpson, T. R. PY - 2014 DA - 2014// TI - Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival JO - Cancer Cell VL - 25 UR - https://doi.org/10.1016/j.ccr.2014.04.005 DO - 10.1016/j.ccr.2014.04.005 ID - Özdemir2014 ER - TY - JOUR AU - Rhim, A. D. AU - Oberstein, P. E. AU - Thomas, D. H. AU - Mirek, E. T. AU - Palermo, C. F. AU - Sastra, S. A. PY - 2014 DA - 2014// TI - Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma JO - Cancer Cell VL - 25 UR - https://doi.org/10.1016/j.ccr.2014.04.021 DO - 10.1016/j.ccr.2014.04.021 ID - Rhim2014 ER - TY - JOUR AU - D’Angelo, R. C. AU - Wicha, M. S. PY - 2010 DA - 2010// TI - Stem cells in normal development and cancer JO - Prog Mol Biol Transl Sci VL - 95 UR - https://doi.org/10.1016/B978-0-12-385071-3.00006-X DO - 10.1016/B978-0-12-385071-3.00006-X ID - D’Angelo2010 ER - TY - JOUR AU - Buczacki, S. PY - 2015 DA - 2015// JO - Cancer Stem Cells Encycl Cell Biol VL - 3 ID - Buczacki2015 ER - TY - JOUR AU - Shapiro, I. M. AU - Kolev, V. N. AU - Vidal, C. M. AU - Kadariya, Y. AU - Ring, J. E. AU - Wright, Q. PY - 2014 DA - 2014// TI - Merlin deficiency predicts FAK inhibitor sensitivity: A synthetic lethal relationship JO - Sci Transl Med VL - 6 UR - https://doi.org/10.1126/scitranslmed.3008639 DO - 10.1126/scitranslmed.3008639 ID - Shapiro2014 ER - TY - JOUR AU - Zhang, Y. AU - Liu, D. AU - Chen, X. AU - Li, J. AU - Li, L. AU - Bian, Z. PY - 2010 DA - 2010// TI - Secreted Monocytic miR-150 enhances targeted endothelial cell migration JO - Mol Cell VL - 39 UR - https://doi.org/10.1016/j.molcel.2010.06.010 DO - 10.1016/j.molcel.2010.06.010 ID - Zhang2010 ER - TY - JOUR AU - Goedegebuure, P. AU - B. Mitchem, J. AU - R. Porembka, M. AU - C.B. Tan, M. AU - A. Belt, B. AU - Wang-Gillam, A. AU - E. Gillanders, W. AU - G. Hawkins, W. AU - C. Linehan, D. PY - 2011 DA - 2011// TI - Myeloid-Derived Suppressor Cells: General Characteristics and Relevance to Clinical Management of Pancreatic Cancer JO - Current Cancer Drug Targets VL - 11 UR - https://doi.org/10.2174/156800911796191024 DO - 10.2174/156800911796191024 ID - Goedegebuure2011 ER - TY - STD TI - Sood AK, Coffin JE, Schneider GB, Fletcher MS, DeYoung BR, Gruman LM, et al. Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion. Am J Pathol. 2004. ID - ref107 ER - TY - JOUR AU - Bueno, R. a. p. h. a. e. l. AU - Gill, R. i. t. u. R. AU - Lizotte, P. a. t. r. i. c. k. H. AU - Sprott, K. a. m. AU - Jackman, D. a. v. i. d. M. i. c. h. a. e. l. AU - Barlow, J. u. l. i. a. n. n. e. AU - Sharma, S. r. i. s. t. i. AU - Yeap, B. e. o. w. Y. AU - Chirieac, L. u. c. i. a. n. R. AU - Lebenthal, A. b. r. a. h. a. m. AU - Cavanaugh, M. e. g. a. n. AU - Rode, A. m. a. n. d. a. J. AU - Kirschmeier, P. a. u. l. AU - Kwiatkowski, D. a. v. i. d. J. AU - Wong, K. w. o. k. -. K. i. n. AU - Richards, W. i. l. l. i. a. m. G. AU - Weaver, D. a. v. i. d. T. PY - 2017 DA - 2017// TI - Effect of FAK inhibitor defactinib on tumor immune changes and tumor reductions in a phase II window of opportunity study in malignant pleural mesothelioma (MPM) JO - Journal of Clinical Oncology VL - 35 UR - https://doi.org/10.1200/JCO.2017.35.15_suppl.8555 DO - 10.1200/JCO.2017.35.15_suppl.8555 ID - Bueno2017 ER - TY - JOUR AU - Patel, M. a. n. i. s. h. R. AU - Infante, J. e. f. f. r. e. y. R. AU - Moore, K. a. t. h. l. e. e. n. N. AU - Keegan, M. i. t. c. h. e. l. l. AU - Poli, A. n. n. e. AU - Padval, M. a. h. e. s. h. AU - Jones, S. u. z. a. n. n. e. F. i. e. l. d. s. AU - Horobin, J. o. a. n. n. a. AU - Burris, H. o. w. a. r. d. A. PY - 2014 DA - 2014// TI - Phase 1/1b study of the FAK inhibitor defactinib (VS-6063) in combination with weekly paclitaxel for advanced ovarian cancer JO - Journal of Clinical Oncology VL - 32 UR - https://doi.org/10.1200/jco.2014.32.15_suppl.5521 DO - 10.1200/jco.2014.32.15_suppl.5521 ID - Patel2014 ER -